Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
New Horizon Health Ltd
6606New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China. Address: T1 Building, Hangzhou, China, 310052
Analytics
Precio Objetivo de WallStreet
359.54 HKDRelación P/E
58.9167Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 6606
Análisis de dividendos 6606
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 6606
Valoración de la acción 6606
Finanzas 6606
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |